Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE.

J Clin Oncol. 2013 Apr 20;31(12):1539-47. doi: 10.1200/JCO.2012.45.2722. Epub 2013 Mar 25.

PMID:
23530101
2.

Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors.

Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL.

Urology. 2004 Jan;63(1):46-50. Review.

PMID:
14751346
3.

Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review.

Ozola Zalite I, Zykus R, Francisco Gonzalez M, Saygili F, Pukitis A, Gaujoux S, Charnley RM, Lyadov V.

Pancreatology. 2015 Jan-Feb;15(1):19-24. doi: 10.1016/j.pan.2014.11.006. Epub 2014 Dec 4. Review.

PMID:
25524484
4.

Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact.

Prado CM, Cushen SJ, Orsso CE, Ryan AM.

Proc Nutr Soc. 2016 May;75(2):188-98. doi: 10.1017/S0029665115004279. Epub 2016 Jan 8. Review.

PMID:
26743210
5.

Definition and classification of cancer cachexia: an international consensus.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE.

Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7. Epub 2011 Feb 4. Review.

PMID:
21296615
6.

Cachexia in patients with oesophageal cancer.

Anandavadivelan P, Lagergren P.

Nat Rev Clin Oncol. 2016 Mar;13(3):185-98. doi: 10.1038/nrclinonc.2015.200. Epub 2015 Nov 17. Review.

PMID:
26573424
7.

Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score.

Douglas E, McMillan DC.

Cancer Treat Rev. 2014 Jul;40(6):685-91. doi: 10.1016/j.ctrv.2013.11.007. Epub 2013 Nov 28. Review.

PMID:
24321611
8.

The emerging role of computerized tomography in assessing cancer cachexia.

Prado CM, Birdsell LA, Baracos VE.

Curr Opin Support Palliat Care. 2009 Dec;3(4):269-75. doi: 10.1097/SPC.0b013e328331124a. Review.

PMID:
19667996
9.

Diagnostic criteria for cancer cachexia: data versus dogma.

Martin L.

Curr Opin Clin Nutr Metab Care. 2016 May;19(3):188-98. doi: 10.1097/MCO.0000000000000272. Review.

PMID:
26945342
10.

Rheumatoid cachexia and cardiovascular disease.

Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD.

Nat Rev Rheumatol. 2010 Aug;6(8):445-51. doi: 10.1038/nrrheum.2010.105. Epub 2010 Jul 20. Review.

PMID:
20647995
11.

The assessment and impact of sarcopenia in lung cancer: a systematic literature review.

Collins J, Noble S, Chester J, Coles B, Byrne A.

BMJ Open. 2014 Jan 2;4(1):e003697. doi: 10.1136/bmjopen-2013-003697. Review.

12.

Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics.

Prado CM, Maia YL, Ormsbee M, Sawyer MB, Baracos VE.

Anticancer Agents Med Chem. 2013 Oct;13(8):1197-203. Review.

PMID:
23919745
13.

Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses.

Baracos V, Kazemi-Bajestani SM.

Int J Biochem Cell Biol. 2013 Oct;45(10):2302-8. doi: 10.1016/j.biocel.2013.06.016. Epub 2013 Jun 29. Review.

PMID:
23819995
14.

Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes.

Kazemi-Bajestani SM, Mazurak VC, Baracos V.

Semin Cell Dev Biol. 2016 Jun;54:2-10. doi: 10.1016/j.semcdb.2015.09.001. Epub 2015 Sep 3. Review.

PMID:
26343952

Supplemental Content

Support Center